Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia


  • Study type

  • Study phase

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

  • Site IRB
    • Rochester, Minnesota: 13-004392
    NCT ID: NCT01841723
    Sponsor Protocol Number: OSU-12200

About this study

This phase II trial studies how well ibrutinib works in treating patients with relapsed hairy cell leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Study closed to enrollment

Inclusion Criteria:

  • Histologically confirmed diagnosis of hairy cell leukemia or variant according to World Health Organization (WHO) criteria
  • Hemoglobin < 11 g/dL
  • Platelet count < 100,000/mL
  • Absolute neutrophil count < 1,000/mL
  • Progressive or symptomatic splenomegaly or hepatomegaly
  • Enlarging lymphadenopathy ≥ 2 cm
  • Absolute lymphocyte count > 5,000/mL
  • Disease related constitutional symptoms consisting of unexplained weight loss exceeding 10% of body weight over the preceding 6 months, Cancer Therapy Evaluation Program (CTEP) active version of the Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or 3 fatigue, fevers > 100.5º Fahrenheit (F) or night sweats for greater than 2 weeks without evidence of infection
  • Patients with classic hairy cell leukemia may receive therapy under the following conditions:
    • After at least 1 prior purine nucleoside analog-containing regimen (fludarabine, pentostatin, or cladribine), or
    • Relapsed or de novo disease if deemed medically unfit for therapy with a purine nucleoside analog
      • Both previously treated and previously untreated patients with this diagnosis will be eligible
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)
  • Life expectancy of greater than 12 months
  • Creatinine ≤ 2.0 mg/dL, and/or creatinine clearance (estimated glomerular filtration rate [GFR] [Cockcroft-Gault]) ≥ 30 mL/min
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless disease related or due to Gilbert's disease)
  • Aspartate aminotransferase (AST) ≤ 2 x ULN (unless disease related)
  • Patients will be eligible without respect to baseline peripheral blood cell counts if they otherwise meet inclusion criteria
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 4 months after completion of ibrutinib treatment; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of ibrutinib administration
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier Patients who are receiving any other investigational agents
  • Patients with known brain metastases should be excluded from this clinical trial
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition as ibrutinib
  • Any medications or substances that are strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)/5 and/or cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) (e.g., itraconazole, ketoconazole, clarithromycin, and bupropion) should be discontinued; patients unable to change these medications must be excluded from participation
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
  • Human immunodeficiency virus (HIV)-positive patients will be eligible unless they have been previously diagnosed with an acquired immune deficiency syndrome (AIDS)-defining illness
  • Patients who require anticoagulation with warfarin (Coumadin) or who have taken warfarin within 28 days prior to enrollment are not eligible; patients who are currently taking vitamin K antagonists are also ineligible for this study
  • Concurrent corticosteroid treatment (equivalent to prednisone > 20 mg daily) is prohibited from 7 days prior to first dose and during treatment with ibrutinib
  • Prior exposure to ibrutinib
  • Major surgery within 10 days or minor surgery within 5 days prior to the first dose of study drug
  • A history of prior malignancy, with the exception of the following:
    • Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to screening, and felt to be at low risk for recurrence by the treating physician
    • Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease
    • Adequately treated cervical carcinoma in situ without current evidence of disease
  • Currently active clinically significant cardiovascular disease such as: uncontrolled arrhythmia, congestive heart failure, any class 3 or 4 cardiac disease as defined by the New York Heart Association functional classification or history of myocardial infarction within 6 months prior to first dose with study drug
  • Patient is unable to swallow capsules or has disease significantly affecting gastrointestinal function and/or inhibiting small intestine absorption, such as malabsorption syndrome, resection of the small bowel, or poorly controlled inflammatory bowel disease affecting the small intestine
  • History of stroke or intracranial hemorrhage within 6 months prior to enrollment

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Timothy Call, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office



Mayo Clinic Footer